Underweight: Trim 40-45% via phased execution, retain ≤50% residual for asymmetric upside participation
Underweight rating reflects bear-case alignment on directional sell signal: August 17 Bollinger Upper Band rejection at $149.88 confirms technical distribution, Q2 $85.68B stock issuance represents ~270% dilution arithmetic requiring future equity raises, and 84x TTM P/S on -35.7% net margins offers no margin of safety against macro headwinds. However, the trim preserves asymmetric upside from verified operational inflection (Q2 revenue +92% YoY, gross margin 55.3%, OCF $2.42B), institutional accumulation (Nvidia 123M shares, Alphabet, Harvard $2.2B, NBIM $1.2B), and merger optionality (19% Polymarket odds). Own less of this name, not zero—wait for multiple compression to justifiable levels or verified proof of the AI/Starship thesis before adding.
| Position | Action |
|---|---|
| Price retests $149-150 resistance (Bollinger Upper Band rejection zone) | Trim 15% of SPCX exposure |
| Confirmed close below $147.50 (failed breakout follow-through) | Trim additional 15% of SPCX exposure |
| Ahead of next lockup unlock event | Trim 10-15% of SPCX exposure |
| Residual position management | Cap residual at ≤50% of prior allocation |
| Close below $108 with volume >150M and RSI <40 | Full exit of residual position |
The convergence of historic institutional accumulation (Nvidia, Alphabet, Harvard, Intesa), a Q2 revenue inflection exceeding all prior three quarters combined, a $100B liquidity fortress, and a technically confirmed V-reversal creates an overwhelming risk/reward setup that dwarfs macro concerns.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 135.04 | bullish |
| close_50_sma | 141.91 | bullish |
| close_200_sma | 141.91 | bullish |
| macd | 1.73 | bullish |
| macd_signal | -2.50 | bullish |
| macd_histogram | 4.23 | bullish |
| rsi | 57.92 | neutral |
| atr | 10.61 | neutral |
Support: 135.04 · 141.91 | Resistance: 141.91 · 149.88
The technical picture is strongly bullish: SPCX has completed a V-reversal from 108.37 to 146.23 (~35% gain in 13 sessions), reclaiming both the 50 SMA and 200 SMA at 141.91 with confirmed MACD bullish crossover (histogram 4.23) and RSI at 57.92 offering further upside runway. ATR compression from 18.18 to 10.61 signals the corrective phase has concluded. Immediate resistance sits at the Bollinger Upper Band (149.88), with the 10 EMA (135.04) serving as near-term support. Recommendation: HOLD with bullish bias, using ATR-based stop-loss sizing (~15.90–21.20 buffer) and waiting for pullback to 135.04 or breakout above 149.88 for new entries.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed breakout above $150 on >200M volume sustained 2 sessions
Then: Initiate or add to position on breakout confirmation
Q2 2026 marked an inflection point with revenue exceeding prior three quarters combined
↩ rebuts: “Bear 'negative FCF' argument without context”
EV: +9.6% to +19.9% (target $160-175 on $146 entry, vs $138 stop) · concedes: Bear has legitimate macro concerns (30Y yields at 19-year highs, 85% probability of zero Fed cuts); Real FCF issue exists (negative $16.82B in Q2); Both macro and FCF concerns are already in the current price
SPCX at $146 is a structurally overvalued, dilution-dependent name priced for perfection with no margin for error, trading into resistance after a 35% bear market rally while macro headwinds intensify and dilution continues.
EV: -$146 to $115-120 (downside scenario if 20-30% earnings miss); $135-140 retest expected before any bounce · concedes: Q2 revenue growth of 66% sequential is real if it represents sustained trend (not conceded); Cash position of $93.52B is real, but comes at cost of massive dilution; Institutional ownership from 13F filings confirms large holders have positions — just not that they're accumulating; Polymarket 19% probability suggests non-zero merger chance, just not at current price; Current ratio of 5.12x indicates short-term liquidity is adequate; Nvidia partnership exists and is strategically important, even if concentration risk is real
→ vs conservative: The 'don't sell winners' playbook only works when risk-reward remains favorable; with 6% upside versus 25-35% downside, the asymmetric argument inverts and selling is the high-conviction trade
→ vs conservative: 30-year yields at 19-year highs actively compress growth multiples; 'yields are priced in' ignores the repricing happening right now to 88x forward earnings with negative margins
→ vs conservative: Polymarket 19% merger odds are lottery tickets, not 'asymmetric upside'; treating embedded call options at these odds as a thesis is reckless
→ vs neutral: The 141.91 SMA convergence is a data artifact, not a 'regime change' or true support level; waiting for confirmation means watching the next 10% drawdown in real time
→ vs neutral: MACD histogram at 4.23 after parabolic 35% move is blowoff exhaustion, not 'room to run'; RSI at 57.92 with no defined destination is meaningless momentum
→ vs neutral: 'Trim, don't exit' delays the inevitable; 270% share dilution and $75B annual cash burn gap guarantee future supply events that the market will punish
→ vs neutral: 'Wait for clearer signals' means waiting for the next 13F showing another $40B in issuance; the dilution thesis is not a future risk but a present reality
→ vs neutral: Historical unlocks being 'bullish' requires strong holders absorbing supply; with Intesa already concentrated at 1/3 of US book, the marginal buyer is less confident than the forced seller is desperate
Market Cap
$1.928T
Forward P/E
88.15x
Price/Book
15.14x
52-Week High
$225.64
52-Week Low
$104.83
50-Day Moving Avg
$141.81
200-Day Moving Avg
$141.81
EPS (TTM)
-$1.11
Forward EPS
+$1.66
Revenue (TTM)
$23.04B
Gross Profit (TTM)
$11.95B
Gross Margin (TTM)
~52%
EBITDA (TTM)
$5.90B
Net Income (TTM)
-$8.89B
Operating Margin (TTM)
-1.8%
Net Profit Margin (TTM)
-35.7%
Revenue (Q2 2026)
$7.81B
Revenue (Q1 2026)
$4.69B
Revenue (Q2 2025)
$4.07B
Revenue (Q1 2025)
$4.07B
Gross Profit (Q2 2026)
$4.32B
Gross Margin (Q2 2026)
55%
Cost of Revenue (Q2 2026)
$3.50B
R&D Expense (Q2 2026)
$3.55B
R&D as % of Revenue
~45%
SG&A (Q2 2026)
$0.91B
Operating Income (Q2 2026)
-$143M
Net Income (Q2 2026)
-$541M
Net Income (Q1 2026)
-$4.28B
Normalized EBITDA (Q2 2026)
$2.96B
Cash & Equivalents (Q2 2026)
$93.52B
Cash & Equivalents (Q1 2026)
$15.85B
Short-term Investments (Q2 2026)
$6.49B
Short-term Investments (Q1 2026)
$7.82B
Total Liquid Assets (Q2 2026)
$100.0B
Total Liquid Assets (Q1 2026)
$23.68B
Total Debt (Q2 2026)
$39.71B
Total Debt (Q1 2026)
$30.60B
Long-Term Debt (Q2 2026)
$36.84B
Long-Term Debt (Q1 2026)
$28.73B
Stockholders' Equity (Q2 2026)
$127.22B
Stockholders' Equity (Q1 2026)
$34.53B
Tangible Book Value (Q2 2026)
$113.18B
Tangible Book Value (Q1 2026)
$20.15B
Total Assets (Q2 2026)
$192.77B
Total Assets (Q1 2026)
$102.09B
Working Capital (Q2 2026)
$86.93B
Working Capital (Q1 2026)
$5.30B
Net PPE (Q2 2026)
$66.85B
Net PPE (Q1 2026)
$55.06B
Goodwill
$11.6B
Preferred Stock (Q2 2026)
$0
Preferred Stock (Q1 2026)
$7.05B
Construction-in-Progress on PPE
$12.55B
Current Ratio (Q2 2026)
5.12x
Debt-to-Equity (Q2 2026)
31.2x
Operating CF (Q2 2026)
$2.42B
Operating CF (Q1 2026)
$1.05B
Operating CF (Q2 2025)
-$376M
Operating CF (Q1 2025)
$727M
CapEx (Q2 2026)
-$19.24B
CapEx (Q1 2026)
-$10.11B
CapEx (Q2 2025)
-$2.85B
CapEx (Q1 2025)
-$4.14B
Free Cash Flow (Q2 2026)
-$16.82B
Free Cash Flow (Q1 2026)
-$9.07B
Free Cash Flow (Q2 2025)
-$3.22B
Free Cash Flow (Q1 2025)
-$3.41B
Stock Issuance (Q2 2026)
+$85.60B
Net Stock Issuance (Q1 2026)
+$3.97B
Net Stock Issuance (Q2 2025)
+$4.14B
Net Stock Issuance (Q1 2025)
+$391M
Net Debt Issuance (Q2 2026)
+$7.93B
End Cash (Q2 2026)
$94.35B
End Cash (Q1 2026)
$16.61B
End Cash (Q2 2025)
$15.09B
End Cash (Q1 2025)
$8.48B
Stock-based Compensation (Q2 2026)
$831M
Stock-based Compensation (Q1 2026)
$639M
Diluted Shares Outstanding (Q2 2026)
5.86B
Common Shares Outstanding (Q2 2026)
13.18B
Book Value per Share (Q2 2026)
$9.66
Strengths
Concerns
SPCX is a $1.93T market cap aerospace/defense company positioned as a hyper-growth platform rather than a traditional OEM, with Q2 2026 revenue surging 66% sequentially to $7.81B and operating cash flow reaching $2.42B, though the company remains GAAP unprofitable on a TTM basis (-$8.89B net loss) due to massive R&D (~45% of revenue) and CapEx (~245% of revenue) intensity. The historic $85.7B equity raise in Q2 2026 dramatically strengthened the balance sheet to $93.52B in cash against $39.71B in debt, providing multi-year runway, but the 88x forward P/E and -$16.82B quarterly FCF deficit demand near-perfect execution on Starship commercialization and Starlink subscriber growth to justify the premium valuation.
Macro: 30-year Treasury yield at 19-year high (multi-source: IBD, Barron's, Reuters, MT Newswires), briefly touching levels not seen since 2007; bond rout driven by oil supply concerns and heavy Treasury supply. Fed policy: Polymarket shows 85% probability of ZERO rate cuts in 2026 (down 0.5pp on $7.3M volume), with hawkish hold stance pressuring long-duration growth assets. Geopolitics: Trump threats on Oman + US-Iran ceasefire expiry pushed crude higher; Libya pipeline dynamics flagged as next potential oil shock; US equity indexes slipped ~0.5% Monday on risk-off action. Defensive rotation into gold/silver underway. Key macro green light: 30Y yield below 4.85%.